bay94-9027
Prophylaxis of Bleeding
BayerPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Prophylaxis of Bleeding cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Damoctocog Alfa Pegol Bayer | Phase 4 | BBB |
Rivaroxaban Brigham and Women's Hospital | Phase 4 | BBB |
WARFARIN Asan Medical Center | Phase 4 | BBB |
Recombinant Human Plasminogen Activator Hamilton Health Sciences Corporation | Phase 4 | BB |
HUMAN FIBRINOGEN University Health Network, Toronto | Phase 4 | BB |
View all 24 →
Same molecule, other indications
bay94-9027 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →